Adjuvant Interferon Alpha 2b in High Risk Melanoma – The Scottish Study
Author Information
Author(s): Cameron D A, Cornbleet M C, Mackie R M, Hunter J A A, Gore M, Hancock B, Smyth J F
Primary Institution: Scottish Melanoma Group
Hypothesis
Does 6 months of low-dose interferon α therapy improve disease-free survival in patients with high-risk melanoma?
Conclusion
The study suggests that 6 months of low-dose interferon α therapy is active, but the long-term survival benefits were not statistically significant.
Supporting Evidence
- 6 months of low-dose interferon α resulted in improved disease-free survival for up to 24 months after randomization.
- There were no toxic deaths, and no patient failed to complete the treatment for reasons of toxicity.
- At a median follow-up of over 6 years, the apparent improvement in disease-free survival was not statistically significant.
Takeaway
This study looked at whether a treatment called interferon helps people with a type of skin cancer called melanoma. It found that while the treatment seemed to help at first, it didn't show a big difference in survival over a long time.
Methodology
A randomized trial comparing observation alone with 6 months of low-dose interferon α therapy in patients with high-risk melanoma.
Limitations
The trial was closed early with a small sample size, and long-term survival differences were not statistically significant.
Participant Demographics
Patients with primary melanomas of at least 3 mm Breslow thickness or with evidence of regional node involvement.
Statistical Information
P-Value
P< 0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website